IOVANCE BIOTHERAPEUTICS Files Q1 2025 10-Q
Ticker: IOVA · Form: 10-Q · Filed: May 8, 2025 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
Related Tickers: IOVA
TL;DR
IOVANCE BIOTHERAPEUTICS (IOVA) filed Q1 2025 10-Q. Financials updated.
AI Summary
IOVANCE BIOTHERAPEUTICS, INC. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Lion Biotechnologies, Inc., reported financial data for the first quarter of 2025. Key financial figures such as retained earnings and additional paid-in capital as of March 31, 2025, were disclosed.
Why It Matters
This filing provides investors with an update on the financial health and operational status of IOVANCE BIOTHERAPEUTICS, INC. during the first quarter of 2025.
Risk Assessment
Risk Level: medium — Biotechnology companies often carry higher risk due to the nature of drug development and regulatory approvals.
Key Numbers
- 333,934,387 — Series B Preferred Stock (Value of Series B Preferred Stock as of March 31, 2025)
- 0.01 — Series B Preferred Stock (Par value per share of Series B Preferred Stock)
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Filer
- Lion Biotechnologies, Inc. (company) — Former company name
- Genesis Biopharma, Inc (company) — Former company name
- FREIGHT MANAGEMENT CORP (company) — Former company name
- March 31, 2025 (date) — Reporting period end date
- 20250331 (date) — Conformed period of report
- 20250508 (date) — Filed as of date
FAQ
What was the total number of shares outstanding for IOVANCE BIOTHERAPEUTICS, INC. as of March 31, 2025?
The filing does not explicitly state the total number of shares outstanding as of March 31, 2025, but it does mention Series B Preferred Stock with a par value of $0.01.
What were the retained earnings of IOVANCE BIOTHERAPEUTICS, INC. as of March 31, 2025?
The filing indicates that retained earnings data is available as of March 31, 2025, but the specific dollar amount is not provided in this excerpt.
What was the additional paid-in capital for IOVANCE BIOTHERAPEUTICS, INC. on March 31, 2025?
The filing references additional paid-in capital as of March 31, 2025, but the specific value is not detailed in this section.
When did IOVANCE BIOTHERAPEUTICS, INC. change its name from Lion Biotechnologies, Inc.?
IOVANCE BIOTHERAPEUTICS, INC. changed its name from Lion Biotechnologies, Inc. on October 15, 2013.
What is the Standard Industrial Classification code for IOVANCE BIOTHERAPEUTICS, INC.?
The Standard Industrial Classification code for IOVANCE BIOTHERAPEUTICS, INC. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding IOVANCE BIOTHERAPEUTICS, INC. (IOVA).